ライフサイエンスコーパス: 18F

1 18F-AV-1451 binding to the basal ganglia was strong in a

2 18F-AV-1451 binding was increased in semantic variant pr

3 18F-CP18 may be useful for detection of anthracycline-in

4 18F-DOPA imaging, however, suggested that intermittent c

5 18F-DOPA PET imaging demonstrated a significantly increa

6 18F-FDG PET is an early predictor of survival in patient

7 18F-FDG PET/CT scans of gluteal and quadriceps muscle ar

8 18F-FDG PET/CT showed bilateral hypermetabolic adrenal m

9 18F-FDG-PET/CT accuracy was determined in the subgroups

10 18F-flortaucipir SUVRs in subcortical regions were highe

11 (18F-Fluoride Assessment of Aortic Bioprosthesis Durabili

12 18F-Fluoride positron emission tomography (PET) and comp

13 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tom

14 18F-fluorodeoxyglucose positron emission tomography was

15 18F-fluorodeoxyglucose positron emission tomography/comp

16 18F-fluorodeoxyglucose-positron emission tomography scan

17 18F-flutemetamol PET was performed in 321 subjects.

18 18F-MK-6240 shows promise as a sensitive biomarker for d

19 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose

20 [18F]-10b and [18F]-10a showed comparable striatum-to- ce

21 [18F]-FDG PET-CT scans revealed a relative increase in gl

22 [18F]F-AraG may be useful for imaging activated T cells i

23 [18F]F-AraG PET imaging of a murine aGVHD model enabled v

24 [18F]fluoro-2-deoxy-D-glucose uptake rate was computed fo

25 d 6 thoracic (thoracic aortic), who had >/=1 18F-FDG positron emission tomography/computed tomography

26 PET/CT interpreters analyzing a subset of 13 18F-fluoride PET/CT scans.

27 : Imaging with fluorine 18-labeled AV-1451 ([18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET

28 gs measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging

29 mean age+/-SD, 65.7+/-14.2 y) underwent 158 18F-fluoride PET/CT scans for evaluation of skeletal met

30 individuals underwent fludeoxyglucose F 18 ([18F]-FDG) positron emission tomographic scanning for ass

31 e symptoms who underwent flutemetamol F 18 ([18F]flumetamol) positron emission tomography amyloid ima

32 2014) who had undergone flutemetamol F 18 ([18F]flutemetamol)-labeled PET.

33 icipants were studied with florbetapir F 18 [18F] PET.

34 w that a novel PET radiotracer, 2'-deoxy-2'-[18F]fluoro-9-beta-D-arabinofuranosylguanine ([18F]F-AraG

35 al present their experience with 2-deoxy-2-[18F] fluoroglucose/positron emission tomography (FDG/PET

36 2-Deoxy-2-[18F]fluoro-D-glucose (2-FDG) with positron emission tomo

37 he radiolabeled CB1 antagonist (3R,5R)-5-(3-(18F-fluoromethoxy)phenyl)-3-(((R)-1-phenylethyl)amino)-1

38 al biodistribution and kinetics of (S)-4-(3-[18F]fluoropropyl)-l-glutamic acid ((18)F FSPG) in health

39 of illness) and 48 older (age 30 years; 30M/18F) patients were age-matched to younger and older heal

40 lus two 18F-labeled PET reporters FHBG [9-(4-18F-fluoro-3-[hydroxymethyl] butyl) guanine] and FLT (18

41 n be estimated using alpha-methyl-4-deoxy-4-[18F]fluoro-D-glucopyranoside (Me-4FDG).

42 Sixty-five younger (age <30 years; 47M/18F) patients with psychosis (all experiencing a first e

43 clusion Findings with 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-p

44 en PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-p

45 Abnormal 18F-flutemetamol retention levels correlate with disease

46 The inclusion of abnormal 18F-FDG cardiac uptake as a major criterion at admission

47 benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA).

48 (R,S)-18F-fluoro-6-thia-heptadecanoic acid ([18F]-FTHA), consistent with upregulation of genes associ

49 y, we evaluate a T-cell-specific PET agent, [18F]F-AraG, as an imaging biomarker predictive of respon

50 underwent fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopam

51 nsufflated with CO2 to displace the lung, an 18F sheath was delivered to the left atrium, and the lef

52 An [18F]-AV-1451 SUVR cutoff value of 1.19 (sensitivity, 100

53 nstance, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in posit

54 ositive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespr

55 en Abeta classification with CSF Abeta42 and 18F-flutemetamol positron emission tomography was very h

56 indicated weak associations between age and 18F-MK-6240 in tangle-associated regions, which were neg

57 bination of functional (high density EEG and 18F-fluorodeoxyglucose PET imaging) and structural (diff

58 nt accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting resi

59 he accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease after ne

60 positivity between 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET

61 We compared 18F-NaF and 18F-FDG uptake with histological characterization of the

62 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel bio

63 ty of locus coeruleus pigmented neurons, and 18F-dihydroxyphenylalanine (FDOPA) PET to assess putamin

64 between inflammatory infiltrate patterns and 18F-FDG-PET/CT uptake were investigated in an explorator

65 Alzheimer's disease slices with 11C-PBB3 and 18F-AV-1451 were noted.

66 ith differential affinities for 11C-PBB3 and 18F-AV-1451, and higher availability of binding sites on

67 11C-PiB PET and 18F-flortaucipir uptake was quantified in a sample of 13

68 based on 11C-Pittsburgh compound B (PiB) and 18F-MK-6240 PET imaging.

69 ation between the CSF tau368/t-tau ratio and 18F-GTP1 retention.

70 BAT volume and 18F-FDG uptake were not associated with quantified ad li

71 vestigate the associations of BAT volume and 18F-fluordeoxyglucose (18F-FDG) uptake after a personali

72 [18F]-10b and [18F]-10a showed comparable striatum-to- cerebellum ratio

73 lation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives of 8 in the brai

74 kin lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demo

75 We sought to compare antemortem 18F-flortaucipir PET to neuropathology in a consecutive

76 8F]fluoro-9-beta-D-arabinofuranosylguanine ([18F]F-AraG), targeted toward two salvage kinase pathways

77 Arterial 18F-NaF uptake was quantified at the level of the ascend

78 demonstrated that quantification of arterial 18F-NaF uptake is affected by blood activity, injected d

79 ted dose affected quantification of arterial 18F-NaF uptake, whereas renal function and circulating t

80 hnical factors on quantification of arterial 18F-NaF uptake.

81 /CT system affect quantification of arterial 18F-NaF uptake.

82 actors can affect quantification of arterial 18F-NaF uptake.

83 d to generate accurate estimates of arterial 18F-NaF uptake.

84 rtaucipir (18F) (flortaucipir, also known as 18F-AV-1451 or 18F-T807) have made it possible to invest

85 as flortaucipir (18F-AV-1451, also known as 18F-T807) have made it possible to investigate the seque

86 d AV-1451 ([18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET, magnetic resonance imaging (MRI

87 Baseline 18F-NaF uptake correlated closely with the change in cal

88 Neither BAT volume, nor BAT 18F-FDG uptake after cold stimulation, are related to ap

89 apsed after meal consumption nor that of BAT 18F-FDG uptake x time elapsed after meal consumption had

90 BAT volume, BAT 18F-FDG uptake, and skeletal muscle 18F-FDG uptake were

91 nd cognitive tests, and associations between 18F-MK-6240, 11C-PiB, and age.

92 pocampus and amygdala, were observed between 18F-MK-6240 and global 11C-PiB in regions associated wit

93 dependent regressions were performed between 18F-AV-1451 binding and each cognitive domain, and we us

94 ting amyloid beta (Abeta) positivity between 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) positro

95 As a promising striatal imaging biomarker, [18F]MNI-659 is potentially capable of assessing the exte

96 ng an association between cognition and both 18F-AV-1451 uptake and grey matter volume.

97 n-fluent variant), 28 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control su

98 lthy subjects were prospectively examined by 18F-NaF PET/CT imaging.

99 of cortical or subcortical hypometabolism by 18F-FDG PET is an unfavorable predictor.

100 We report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/comp

101 sments of in vivo tau pathology (measured by 18F-AV-1451 PET), neuroinflammation (measured by 11C-PK1

102 nal brain nAChR availability, as measured by 18F-F-A-85380 binding potential (BP), using linear regre

103 t levels of brain Abeta fibrils (measured by 18F-flutemetamol PET) are independently associated with

104 ng to diagnostic classifications provided by 18F-FDG PET at baseline and clinical diagnoses after a m

105 ethylation status, and metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

106 Risk stratification by 18F-FDG PET appears to be at least as predictive as the

107 best-fitting model to assess SMGU studied by 18F-FDG.

108 ge in BAT metabolic activity as measured by [18F]-2-fluoro-d-2-deoxy-d-glucose (18F-FDG) PET/CT.

109 und effect on Patlak kinetics and calculated 18F-FDG uptake.

110 a caspase-3 substrate and evaluated cardiac 18F-CP18 uptake in a mouse model of anthracycline cardio

111 We compared 18F-NaF and 18F-FDG uptake with histological characteriz

112 (95% CI, 11-24 years) for the mean cortical 18F-florbetapir standard uptake value ratio, age 15 year

113 Results: In patients with DLB, cortical [18F]AV-1451 uptake was highly variable and greater than

114 Elevated cortical [18F]AV-1451 binding was observed in 4 of 17 patients wit

115 den with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT) and evaluate the reproducibility of

116 ed better to clinical heterogeneity than did 18F-AV-1451: distinct spatial modes of neuroinflammation

117 The 2-dimensional and 3-dimensional 18F-DTBZ PET images demonstrated that the reduction of v

118 lative to patients with Alzheimer's disease, 18F-AV-1451 binding was elevated in the midbrain (t = 2.

119 e oximetry were measured in patients during [18F]FMISO and 15O PET imaging.

120 healthy male volunteers underwent 2 dynamic 18F-FDG PET/CT scans with an interval of 24 h.

121 nsulin treatment, reflecting the rapid early 18F-FDG uptake.

122 e of Abeta+ was associated with an elevated [18F]-AV-1451 SUVR in AD cortical signature regions (Abet

123 An elevated [18F]-AV-1451 SUVR was associated with volumetric loss in

124 and the impact of an end-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET

125 in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic labelling of these tissues.

126 u-targeted PET tracers such as flortaucipir (18F) (flortaucipir, also known as 18F-AV-1451 or 18F-T80

127 ion tomography tracers such as flortaucipir (18F-AV-1451, also known as 18F-T807) have made it possib

128 nous administration of 370 MBq flortaucipir (18F).

129 o-3-[hydroxymethyl] butyl) guanine] and FLT (18F-3'-deoxy-3-'fluorothymidine), respectively.

130 ons of BAT volume and 18F-fluordeoxyglucose (18F-FDG) uptake after a personalized cold exposure with

131 Sodium 18F-fluoride (18F-NaF) PET/CT imaging is a promising imaging technique

132 18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promis

133 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel biomarkers of disease activ

134 oropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives of 8 in the brain.

135 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a PET tracer that undergoes irreversible sel

136 mediated accumulation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]-10a) derivatives o

137 95 PET, and matched control subjects (14 for 18F-AV-1451 and 15 for 11C-PK-11195).

138 and advanced stages of PD were recruited for 18F-DTBZ PET scans from the Movement Disorders Clinic in

139 Regional uptakes for 18F-DTBZ PET of different disease stages were measured.

140 -CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practi

141 sured by [18F]-2-fluoro-d-2-deoxy-d-glucose (18F-FDG) PET/CT.

142 plored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in c

143 us brain regions was associated with greater 18F-AV-1451 PET retention most prominently in the inferi

144 For DLB and PD-impaired patients, greater [18F]AV-1451 uptake in the inferior temporal gyrus and pr

145 An inverse association between hippocampal [18F]-AV-1451 SUVR and volume was seen in Abeta+ particip

146 uantification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET

147 We found that: (i) 18F-AV-1451 positron emission tomography retention was d

148 a proxy index of neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pat

149 t scans, 19 post-treatment scans); and (iii) 18F-fallypride imaging of an antipsychotic free Alzheime

150 sorders, and had completed amyloid imaging ([18F]-florbetapir) at baseline and cognitive assessments

151 A similar increase in 18F-CP18 uptake was observed by microPET (0.41+/-0.04 ve

152 The differences in [18F]F-AraG signal were also apparent between responders

153 Increased 18F-FDG positron emission tomographic uptake in aortic a

154 alsy showed, relative to controls, increased 18F-AV-1451 uptake in the putamen, pallidum, thalamus, m

155 strated >/=1 aneurysm wall area of increased 18F-FDG uptake.

156 We also show that increased 18F-FDG uptake in non-metastatic nodes can be explained

157 ance in each domain was related to increased 18F-AV-1451 binding in specific brain regions conforming

158 There was increased 18F-AV-1451 binding in multiple regions in living patien

159 icin treatment was associated with increased 18F-CP18 uptake in %ID/g by gamma counting from 0.36+/-0

160 l events occurred in patients with increased 18F-FDG uptake on their last examination than in those w

161 suggested that the threshold for increased [18F]FMISO trapping is probably 15 mm Hg or lower.

162 Foci of increased [18F]AV-1451 binding in the inferior temporal gyrus and p

163 hypometabolism typically seen on interictal 18F-fluorodeoxyglucose PET imaging in patients with foca

164 One hour later, 18F-FDG was injected, followed by a 3-h dynamic PET scan

165 erence between bSUVmax of the most and least 18F-fluorodeoxyglucose-avid lymphoma sites) was 8.0 (ran

166 ervention Alzheimer's Prevention Trial (MAPT-18F AV45-PET; n = 23) cohorts.

167 coronary arteries by calculating the maximum 18F-NaF activity (NaFmax), the maximum/mean target-to-ba

168 cerebellar grey matter reference, 80-100-min 18F-flortaucipir PET standardized uptake value ratio (SU

169 lymph node of TRL-positive patients misleads 18F-FDG-PET/CT for detecting nodal metastasis.

170 e demonstrate that pretreatment TRL misleads 18F-FDG-PET/CT during lymph node staging in gynecologica

171 structural and diffusion tensor imaging MRI, 18F-fluorodeoxyglucose and Pittsburgh compound B PET.

172 ume, BAT 18F-FDG uptake, and skeletal muscle 18F-FDG uptake were assessed by means of static 18F-FDG

173 ty and specificity of positive and negative [18F] florbetapir PET categorization, which was estimated

174 were not associated with Abeta isoforms nor 18F-flutemetamol uptake.

175 resonance imaging-based spatially normalized 18F-DTBZ images for each participant.

176 The observed [18F]-AV-1451 SUVR volumetric association was modified by

177 as excellent correspondence between areas of 18F-flortaucipir retention, on both SUVR images and W-sc

178 grey matter volumes, and regional binding of 18F-AV-1451 and 11C-PK11195 were derived from 15 temporo

179 ctive model that included both components of 18F-AV-1451 and the first (i.e. anterior temporal) compo

180 h direct and grey matter-mediated effects of 18F-AV-1451 uptake on cognitive performance.

181 uromelanin is an insufficient explanation of 18F-AV-1451 positron emission tomography data in vivo, a

182 research investigating the interpretation of 18F-NaF PET activity is necessary.

183 d ECG-gated PET-CT permitted localization of 18F-fluoride uptake to individual valve leaflets.

184 ponding to the cortical distribution maps of 18F-T807 and 11C-PiB.

185 A composite measure of 18F-flutemetamol uptake was not associated with WML, and

186 Cross-sectional measures of 18F-florbetapir positron emission tomography, 18F-fludeo

187 e after intravenous injection of 250 muCi of 18F-CP18, 24 hours post-doxorubicin treatment was quanti

188 tosis (TRL) on the diagnostic performance of 18F-FDG-PET/CT in detecting pelvic and paraaortic lymph

189 Overall, we confirm the potential of 18F-AV-1451 as a heuristic biomarker, but caution is ind

190 inding may contribute to disease profiles of 18F-AV-1451 positron emission tomography, especially in

191 Quantification of 18F-flortaucipir SUVR images at Braak stage regions of i

192 We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD wh

193 What is the sensitivity and specificity of 18F-fludeoxyglucose-positron emission tomography/compute

194 Use of 18F-FDG-PET/CT at the initial presentation of patients w

195 , there is limited evidence regarding use of 18F-FDG-PET/CT for the diagnosis of native valve endocar

196 s who present with suspected NVE, the use of 18F-FDG-PET/CT is less accurate and could only be consid

197 d positive and negative predictive values of 18F-FDG-PET/CT focal uptake were 93%, 90%, 89%, and 94%,

198 ecipient bone marrow, while accumulation of [18F]-L-FMAU in hdCK3mut-expressing T cells permitted det

199 tratumoral signal came from accumulation of [18F]F-AraG in immune cells, primarily CD8(+) and CD4(+).

200 or cells showed the highest accumulation of [18F]F-AraG.

201 observed the A2AR-mediated accumulation of [18F]fluoropropyl ([18F]-10b) and [18F]fluoroethyl ([18F]

202 of [18F]AV-1451 binding, the association of [18F]AV-1451 binding with [11C]PiB binding, and the assoc

203 th [11C]PiB binding, and the association of [18F]AV-1451 binding with cognitive impairment.

204 iation of diagnostic groups on the basis of [18F]AV-1451 binding, the association of [18F]AV-1451 bin

205 maintained uptake and saturable binding of [18F]GV1-57 in primate nasal epithelium, supporting its t

206 We demonstrate our method on the GWAS of [18F]FDG-PET measures in the amygdala region using the im

207 ls were studied with dynamic PET imaging of [18F]fluoro-2-deoxy-D-glucose at two occasions with 24-ho

208 s strongly correlated with the magnitude of [18F]AV-1451 binding (3 patients with amnesic Alzheimer d

209 imaging arthritis and kinetic properties of [18F]fluoro-PEG-folate in RA patients.

210 Standardized uptake value ratio (SUVR) of [18F]-AV-1451 in the hippocampus and a priori-defined AD

211 With combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR

212 Use of [18F]-AV-1451 has a potential for staging of the preclini

213 The influx constant kicer based on 18F-DOPA-PET was used to measure striatal dopamine synth

214 in aortic target-background ratio (TBR) on [18F]-FDG-PET with combined ART in the HIV-infected group

215 Optimized 18F-fluoride PET-CT allows reproducible localization of

216 (flortaucipir, also known as 18F-AV-1451 or 18F-T807) have made it possible to investigate the seque

217 Aortic Bioprosthesis Durability and Outcome [18F-FAABULOUS]; NCT02304276).

218 Overall, [18F]F-AraG has potential to serve as a much needed immun

219 In PD, 18F-DTBZ PET is a potential imaging biomarker for measur

220 taneous fluorodihydroxyphenyl-l-alanine PET (18F-DOPA-PET) and resting state functional MRI (rs-fMRI)

221 Participants underwent two to four tau-PET (18F-flortaucipir) scans with a mean (+/- standard deviat

222 h compound B (PIB) and MRI, and 577 PIB-PET, 18F-AV1451 flortaucipir PET and MRI.

223 (n = 20, 65-79 years); (ii) pharmacokinetic, 18F-fallypride D2/3 receptor imaging and clinical outcom

224 between age and the mean cortical to pontine 18F-florbetapir standard uptake value ratios, precuneus

225 estigations, we show that the false-positive 18F-FDG-PET/CT result for detecting nodal metastasis can

226 within a mean of 1.6 years, and a positive [18F] florbetapir baseline scan was associated with a 6.9

227 MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemic

228 w prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomogra

229 Based on clinical profile, 18F-fluorodeoxyglucose-positron emission tomography imag

230 a follow-up of up to 5.9 y after prospective 18F-FDG PET imaging.

231 We assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to

232 Using cerebellar gray reference, 18F-T807 data were expressed as standardized uptake valu

233 ke was not associated with WML, and regional 18F-flutemetamol uptake only with temporal WML.

234 ents with aortic stenosis underwent repeated 18F-fluoride PET-CT.

235 a completely negative scan or with residual [18F]FDG activity below the mediastinal blood pool (MBP)

236 g the palmitic acid surrogate tracer 14(R,S)-18F-fluoro-6-thia-heptadecanoic acid ([18F]-FTHA), consi

237 (7 males/8 females) using the oral 14(R,S)-[18F]-fluoro-6-thia-heptadecanoic acid positron emission

238 Sodium 18F-fluoride (18F-NaF) PET/CT imaging is a promising ima

239 More specifically, 18F-AV-1451 binding was significantly increased in patie

240 -FDG uptake were assessed by means of static 18F-FDG positron-emission tomography and computed tomogr

241 Striatal [18F]MNI-659 uptake correlated strongly with the severity

242 Rmax/mean), and the maximum blood-subtracted 18F-NaF activity (bsNaFmax).

243 We synthesized 18F-CP18, a caspase-3 substrate and evaluated cardiac 18

244 al community underwent flortaucipir 18 T807 (18F-T807) and carbon 11-labeled Pittsburgh Compound B (1

245 C-PiB) positron emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic

246 derwent a combination of laboratory testing, 18F-fluorodeoxyglucose positron emission tomography scan

247 nuclear palsy tau deposits for 11C-PBB3 than 18F-AV-1451.

248 ssociated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomograph

249 ary, PET-to-autopsy comparisons confirm that 18F-flortaucipir PET is a reliable biomarker of advanced

250 ost-mortem autoradiographic data showed that 18F-AV-1451 strongly bound to Alzheimer-related tau path

251 We suggest that 18F-AV-1451 positron emission tomography is a useful bio

252 4F MANTA was used in 42 cases (16%), and the 18F was used in 221 cases(84%).

253 lear palsy, and a control case to assess the 18F-AV-1451 binding specificity to Alzheimer's and non-A

254 We also examined the 18F-AV-1451 autoradiographic binding in post-mortem tiss

255 The [18F]-AV-1451 SUVR in the hippocampus and AD cortical sig

256 r in vivo evidence that distribution of the [18F]AV-1451 signal as seen on results of PET imaging is

257 iated with the regional distribution of the [18F]AV-1451 signal.

258 ative-associated variability; and (iii) this 18F-AV-1451 positron emission tomography retention patte

259 on emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to w

260 ange in florbetapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the p

261 ron emission tomography-computed tomography (18F-FDG-PET/CT) can be influenced by the increased glyco

262 ron emission tomography/computed tomography (18F-FDG-PET/CT) has emerged as a useful diagnostic tool

263 odium fluoride positron emission tomography (18F-NaF PET) scans as target-to-background ratios (TBRs)

264 8F-florbetapir positron emission tomography, 18F-fludeoxyglucose positron emission tomography, struct

265 with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer'

266 and Rluc bioluminescence reporters plus two 18F-labeled PET reporters FHBG [9-(4-18F-fluoro-3-[hydro

267 Andreasen, and 24 healthy controls underwent 18F-DOPA-PET and behavioural-cognitive assessment.

268 Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11

269 cohorts of 10 healthy volunteers underwent [18F]FMISO or 15O PET.

270 ol study included 10 patients who underwent [18F]FMISO and 15O PET within 1 to 8 days of severe or mo

271 pared to age- and sex-matched controls using 18F-2-fluoro-2-deoxy-d-glucose PET (n = 20 per group) an

272 rial and LN inflammation were measured using 18F-fluorodeoxyglucose positron emission tomography.

273 e mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 with 11C-MeAIB, compared with 33.7

274 nding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 with 11C-MeAIB, and 125.4 mm3 by hist

275 histology-derived volumes was obtained using 18F-FDG, MAP3D reconstruction, and fixed thresholding of

276 a deposition was measured at baseline using [18F]florbetapir positron emission tomographic imaging.

277 ge-matched controls born at full term using [18F]-DOPA PET and structural MRI.

278 scan-rescan reproducibility of aortic valve 18F-fluoride PET-CT imaging.

279 icant correlation was noted between valvular 18F-FDG uptake and change in calcium score (r=-0.11; P=0

280 and may show improved agreement with visual [18F]flutemetamol PET assessment when using the Abeta42:A

281 assay showed better concordance with visual [18F]flutemetamol PET status (area under the receiver ope

282 :Abeta40 and Abeta42:tau ratios with visual [18F]flutemetamol PET status.

283 this improved further (r=0.75; P<0.01) when 18F-NaF uptake overlying computed tomography-defined mac

284 This study aimed to determine whether 18F-fludeoxyglucose-positron emission tomography/compute

285 ally high agreement (95%; kappa = 0.89) with 18F-flutemetamol positron emission tomography in the val

286 subjects underwent baseline assessment with 18F-AV-1451 PET, 11C-PK11195 PET, and structural MRI.

287 Determination of skeletal tumor burden with 18F-fluoride PET/CT is feasible and highly reproducible.

288 method to assess skeletal tumor burden with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT)

289 In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scan

290 in a third cohort where the correlation with 18F-GTP1 tau PET was evaluated (Alzheimer's disease = 38

291 ography (PET) imaging study in epilepsy with 18F-FA-85380, a specific marker for alpha4beta2 nAChRs,

292 Dynamic PET imaging with 18F-FDG (7.7+/-0.9 MBq) was conducted.

293 ship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzhe

294 increase active calcification measured with 18F-NaF PET activity compared with placebo, but no effec

295 PET amyloid data were obtained with 18F-flutemetamol (Vizamyl(R)) at baseline and Week 78.

296 ng disease-specific metabolism patterns with 18F-FDG PET compared with that of clinical diagnosis.

297 metabolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomograph

298 Positron emission tomography with 18F-florbetapir and fludeoxyglucose was used to quantify

299 mental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study is a multicenter stud

300 PET with [18F]fluoro-2-deoxy-D-glucose can be used to image cellul